S
Steven P. Conway
Researcher at St James's University Hospital
Publications - 127
Citations - 7851
Steven P. Conway is an academic researcher from St James's University Hospital. The author has contributed to research in topics: Cystic fibrosis & Respiratory function. The author has an hindex of 44, co-authored 127 publications receiving 7332 citations. Previous affiliations of Steven P. Conway include Leeds Teaching Hospitals NHS Trust & Leeds General Infirmary.
Papers
More filters
Journal ArticleDOI
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.
Gerd Döring,Steven P. Conway,H.G.M. Heijerman,Margaret E. Hodson,Niels Høiby,Alan R. Smyth,Daan J Touw +6 more
TL;DR: In this paper, a panel of 34 European experts have discussed the use of antibiotics against Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients and the factors which determine the choice of the antibiotic, the dosage, and the duration of the treatment in CF patients.
Journal ArticleDOI
Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients
TL;DR: The validity and importance of identifying these four subgroups of patients as either 'chronic', 'intermittent', 'free of PA', or 'never infected' is demonstrated.
Journal Article
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis
Gerd Döring,Steven P. Conway,H.G.M. Heijerman,Margaret E. Hodson,Niels Høiby,Alan R. Smyth,Daan J Touw +6 more
TL;DR: A consensus statement on regular maintenance treatment, or treatment on demand, was given and different routes of administration of antibiotics were recommended for different clinical situations, and the design of future antibiotic studies in the context of Pseudomonas aeruginosa lung infection in cystic fibrosis patients were recommended.
Journal ArticleDOI
Standards of care for patients with cystic fibrosis: a European consensus
TL;DR: The clinical consequences include multi-system disease characterised by progressive pulmonary damage leading to respiratory failure, pancreatic dysfunction, liver disease that may progress to cirrhosis, gut motility problems, and elevated sweat electrolytes.
Journal ArticleDOI
Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis : A European consensus
TL;DR: The current status of inhaled medication in CF is reviewed, including the mechanisms of action of the various drugs, their modes of administration and indications, their effects on lung function, exacerbation rates, survival and quality of life, as well as side effects.